Therapy
Health
Cancer Prevention

Inovio

$3.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Pre-Market
$0.00 (0.00%) Pre-Market

Why Robinhood?

You can buy or sell Inovio and other stocks, options, ETFs, and crypto commission-free!

About

Inovio Pharmaceuticals, Inc. Common Stock, also called Inovio, is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Read More It focuses on the development of SynCon immunotherapy, which helps break the immune system's tolerance of cancerous cells; and CELLECTRA, which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Employees
281
Headquarters
Plymouth Meeting, Pennsylvania
Founded
1983
Market Cap
350.01M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.02M
High Today
$3.62
Low Today
$3.48
Open Price
$3.52
Volume
405.33K
52 Week High
$6.30
52 Week Low
$3.02

Collections

Therapy
Health
Cancer Prevention
Medical
Pharmaceutical
Technology

News

Simply Wall StMar 18

What You Must Know About Inovio Pharmaceuticals, Inc.’s (NASDAQ:INO) Beta Value

Anyone researching Inovio Pharmaceuticals, Inc. (NASDAQ:INO) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The second type is the broader market volatility, which you cannot diversify away, since it arises...

265
Yahoo FinanceMar 18

Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

On Mar 15, we issued an updated research report on Inovio Pharmaceuticals, Inc. INO. Inovio’s most advanced candidate, VGX-3100 vaccine, has been progressing well alongside other promising pipeline candidates in its portfolio. VGX-3100 is currently being evaluated in a phase III study (REVEAL 1) for the treatment of cervical dysplasia caused by human papillomavirus (HPV). The company has also initiated enrollment in the confirmatory phase III (REVEAL 2) study. It plans to submit a biologics license applic...

257
The Motley FoolMar 14

3 Penny Stocks That Could Make You Rich -- or Regretful

Penny stocks -- or stocks with sub-$5 share prices -- can be tremendous growth vehicles for risk-tolerant investors. By the same token, stocks that trade at these bargain-basement levels often do so for a very good reason, such as large outstanding share counts, poor underlying fundamentals, or recent strategic setbacks. The penny biotech stocks Inovio (NASDAQ:INO), Geron (NASDAQ:GERN), and Verastem (NASDAQ:VSTM) each suffer from one or more of these core problems. Nevertheless, these three companies also ...

6,086

Earnings

-$0.40
-$0.29
-$0.19
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.28 per share
Actual
-$0.34 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.